BOTTA, CIRINO
 Distribuzione geografica
Continente #
EU - Europa 917
NA - Nord America 830
AS - Asia 164
AF - Africa 3
OC - Oceania 1
SA - Sud America 1
Totale 1.916
Nazione #
US - Stati Uniti d'America 829
GB - Regno Unito 391
IE - Irlanda 155
CN - Cina 82
IT - Italia 79
SE - Svezia 60
UA - Ucraina 55
RU - Federazione Russa 47
DE - Germania 44
SG - Singapore 27
FR - Francia 26
FI - Finlandia 18
VN - Vietnam 18
IN - India 15
BE - Belgio 14
TR - Turchia 14
ES - Italia 11
IM - Isola di Man 7
IR - Iran 3
AT - Austria 2
CI - Costa d'Avorio 2
HK - Hong Kong 2
NL - Olanda 2
PL - Polonia 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BD - Bangladesh 1
CA - Canada 1
CL - Cile 1
CZ - Repubblica Ceca 1
LT - Lituania 1
NO - Norvegia 1
PK - Pakistan 1
ZA - Sudafrica 1
Totale 1.916
Città #
Southend 365
Dublin 148
Fairfield 114
Chandler 72
Ashburn 65
Ann Arbor 63
Wilmington 54
Jacksonville 51
Seattle 47
Menlo Park 45
Woodbridge 45
Cambridge 43
Siena 40
Houston 32
Beijing 24
Singapore 21
New York 20
Princeton 20
Dong Ket 18
Dearborn 17
Brussels 14
Fremont 14
Helsinki 13
Izmir 13
Nanjing 13
Málaga 11
Boardman 9
San Mateo 8
Douglas 7
Falls Church 7
Munich 7
Shanghai 6
Shenyang 6
Florence 5
Hebei 5
Lancaster 5
Nanchang 5
San Diego 5
Jinan 4
Tianjin 4
Fuzhou 3
Hangzhou 3
London 3
Moscow 3
Mumbai 3
Phoenix 3
Santa Clara 3
Abidjan 2
Bari 2
Duncan 2
Hong Kong 2
Nardò 2
Sezze 2
Turin 2
Vienna 2
Zanjan 2
Zhengzhou 2
Alghero 1
Amsterdam 1
Andover 1
Bangalore 1
Borghetto Lodigiano 1
Buffalo 1
Campi Bisenzio 1
Canberra 1
Carraia 1
Changsha 1
Dallas 1
Delhi 1
Dhaka 1
Edinburgh 1
Espoo 1
Falkenstein 1
Foligno 1
Gauteng 1
Giussano 1
Henderson 1
Hounslow 1
Islamabad 1
Katowice 1
Kilburn 1
Kocaeli 1
Kunming 1
Kyiv 1
Leawood 1
Messina 1
Modena 1
Ningbo 1
Oslo 1
Ottawa 1
Philadelphia 1
Prague 1
Prato 1
Saint Louis 1
Sandston 1
Taizhou 1
Tirana 1
Warsaw 1
Yerevan 1
Totale 1.548
Nome #
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 249
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 242
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 230
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 216
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab 182
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 174
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 173
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 155
Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy 150
Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP/VAC phase lb program 123
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 69
Totale 1.963
Categoria #
all - tutte 5.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.539


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020264 0 0 0 0 29 43 40 41 42 37 14 18
2020/2021360 18 42 7 34 25 42 8 41 34 59 15 35
2021/2022199 10 24 10 10 21 10 14 10 21 21 14 34
2022/2023249 14 25 35 34 25 46 8 18 16 16 8 4
2023/2024237 8 5 17 13 4 65 108 1 2 4 1 9
2024/2025100 16 16 47 18 3 0 0 0 0 0 0 0
Totale 1.963